Tiotropium therapy and mortality risk in COPD patients: The most severe, the most protected?

Italo Sampablo, Mauro Carone, Sabina Antonela Antoniu

Research output: Contribution to journalArticle


Importance of the field: Tiotropium bromidum is an inhaled long acting anticholinergic used as first line monotherapy in stable COPD due to its beneficial effects on the lung function, respiratory symptoms, quality of life or disease morbidity. However there is limited data on its effects on mortality. Areas covered in this review: The results of the UPLIFT (Understanding Potential Long-Term Impacts on Function with Tiotropium) study evaluating the effects of 4 year therapy with tiotropium on above mentioned outcomes including mortality. What the reader will gain: Tiotropium demonstrated an uniform beneficial effect on mortality risk reduction but subset analyses yielded relevant results as well. Take home message: On long-term basis tiotropium therapy can reduce mortality rate overall and can exert such protective effects in various subsets such as patients with very severe COPD.

Original languageEnglish
Pages (from-to)1439-1441
Number of pages3
JournalExpert Opinion on Pharmacotherapy
Issue number8
Publication statusPublished - Jun 2010


  • COPD
  • Mortality
  • Tiotropium

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint Dive into the research topics of 'Tiotropium therapy and mortality risk in COPD patients: The most severe, the most protected?'. Together they form a unique fingerprint.

  • Cite this